Searle & Co. Incyte Corp Transaction History

Searle & Co.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$52.16 - $64.19 $156,480 - $192,570	-3,000 Reduced 29.27%	7,250 $455,000
Q1 2023 Jun 01, 2023	SELL	$70.23 - $86.01 $14,046 - $17,202	-200 Reduced 1.91%	10,250 $740,000
Q1 2022 May 10, 2022	BUY	$66.02 - $79.71 $316,896 - $382,607	4,800 Added 84.96%	10,450 $830,000
Q3 2021 Oct 08, 2021	BUY	$68.67 - $84.02 $387,985 - $474,713	5,650 New	5,650 $389,000

705

189M

917K

459K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Searle & Co., based on Form 13F filings with the SEC.

Stay updated on Searle & Co. with notifications on news.